The start of a so-called rolling review formally begins an FDA evaluation of a closely watched drug that’s important to the biotech’s future, but faces questions about its sales potential.
Higher doses of Narcan — or naloxone — do not affect the possibility of survival after an overdose. Be cautious.
Vertex Pharmaceuticals has inched closer to bringing a new, non-opioid med to the blockbuster pain market, with the FDA ...
"Nalmefene had been approved in 1995 by the FDA so there is a long history of the effectiveness of Nalmefene in different formulations.” Just like Narcan, giving Opvee to someone who is ...
Purdue Pharma L.P. ("Purdue") announced today that FDA has accepted for filing the company’s New Drug Application (NDA) for the auto-injector delivery form of nalmefene hydrochloride injection*. If ...
Some argue a need for more potent — and pricier — overdose reversal drugs; others frame that effort as drugmakers peddling ...
Physicians said the test is based “on old genetic studies that have largely been abandoned” and could exacerbate the opioid crisis.
The start of the opioid epidemic is ironically linked to a drug that was supposed to help people suffering from moderate to ...
A group of 31 experts in genetics, addiction, psychiatry, and medical-device regulation sent letters to the FDA and Centers for Medicare and Medicaid Services, The Washington Post reported. The ...
With the addition of provider training and postmarket studies required of the manufacturer the FDA approved AvertD last December.
On average, Americans consume about 20 times the amount of prescription opioids as the rest of the world. It is no surprise ...
Purdue Pharma has asked the federal Food and Drug Administration (FDA) to approve a new, auto-injectable form of one of its drugs to treat opioid overdoses. The Stamford-based biopharmaceutical ...